Cannabinoid-based medicine Epidiolex approved for sale in Canada

Canada’s federal health regulator has approved Jazz Pharmaceuticals Canada’s cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain rare and severe forms of epilepsy, allowing the company to bring to market a clinically tested drug with global sales that dwarf those of the nation’s entire medical cannabis industry

Image of a machine filling bottles with Epidiolex